Sectors & IndustriesHealthcareBiotechnology

Best Biotech Stocks to Buy Now (2026)

Top biotech stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best biotech stocks to buy now. Learn More.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best biotechnology stocks to buy right now are:

Mimedx Group (NASDAQ:MDXG) is the #1 top biotech stock out of 610 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Mimedx Group (NASDAQ:MDXG) is: Value: B, Growth: B, Momentum: D, Sentiment: B, Safety: C, Financials: A, and AI: B.

Mimedx Group (NASDAQ:MDXG) has a Due Diligence Score of 42, which is 18 points higher than the biotech industry average of 24.

MDXG passed 13 out of 33 due diligence checks and has strong fundamentals. Mimedx Group has seen its stock lose -35.48% over the past year, underperforming other biotech stocks by -4 percentage points.

Mimedx Group has an average 1 year price target of $9.33, an upside of 79.48% from Mimedx Group's current stock price of $5.20.

Mimedx Group stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Mimedx Group, 66.67% have issued a Strong Buy rating, 33.33% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Biocryst Pharmaceuticals (NASDAQ:BCRX) is the #2 top biotech stock out of 610 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Biocryst Pharmaceuticals (NASDAQ:BCRX) is: Value: B, Growth: A, Momentum: C, Sentiment: B, Safety: C, Financials: B, and AI: C.

Biocryst Pharmaceuticals (NASDAQ:BCRX) has a Due Diligence Score of 15, which is -9 points lower than the biotech industry average of 24. Although this number is below the industry average, our proven quant model rates BCRX as a "A".

BCRX passed 5 out of 33 due diligence checks and has weak fundamentals. Biocryst Pharmaceuticals has seen its stock lose -20.34% over the past year, overperforming other biotech stocks by 11 percentage points.

Biocryst Pharmaceuticals has an average 1 year price target of $21.86, an upside of 192.21% from Biocryst Pharmaceuticals's current stock price of $7.48.

Biocryst Pharmaceuticals stock has a consensus Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Biocryst Pharmaceuticals, 28.57% have issued a Strong Buy rating, 57.14% have issued a Buy, 14.29% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Aurinia Pharmaceuticals (NASDAQ:AUPH) is the #3 top biotech stock out of 610 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Aurinia Pharmaceuticals (NASDAQ:AUPH) is: Value: A, Growth: C, Momentum: B, Sentiment: B, Safety: C, Financials: A, and AI: C.

Aurinia Pharmaceuticals (NASDAQ:AUPH) has a Due Diligence Score of 49, which is 25 points higher than the biotech industry average of 24.

AUPH passed 16 out of 33 due diligence checks and has strong fundamentals. Aurinia Pharmaceuticals has seen its stock return 82.97% over the past year, overperforming other biotech stocks by 115 percentage points.

Aurinia Pharmaceuticals has an average 1 year price target of $17.33, an upside of 20.37% from Aurinia Pharmaceuticals's current stock price of $14.40.

Aurinia Pharmaceuticals stock has a consensus Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Aurinia Pharmaceuticals, 33.33% have issued a Strong Buy rating, 0% have issued a Buy, 66.67% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 5 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 27.82%, which is 22 percentage points higher than the biotech industry average of 5.83%.

Dominari Holdings's dividend payout ratio of 8.4% indicates that its high dividend yield is sustainable for the long-term.

Oramed Pharmaceuticals (NASDAQ:ORMP) has an annual dividend yield of 7.89%, which is 2 percentage points higher than the biotech industry average of 5.83%.

Oramed Pharmaceuticals's dividend payout ratio of 0% indicates that its high dividend yield might not be sustainable for the long-term.

Royalty Pharma (NASDAQ:RPRX) has an annual dividend yield of 1.95%, which is -4 percentage points lower than the biotech industry average of 5.83%. Royalty Pharma's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Royalty Pharma's dividend has shown consistent growth over the last 10 years.

Royalty Pharma's dividend payout ratio of 49.2% indicates that its dividend yield is sustainable for the long-term.

Biotech stocks were up 0.18% in the last day, and up 1.76% over the last week. Pmgc Holdings was the among the top gainers in the biotechnology industry, gaining 17.89% yesterday.

PMGC Holdings shares are trading higher after the company announced that its subsidiary NorthStrive filed 10 new U.S. patent applications for EL-22 and EL-32 technologies.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued biotech stocks right now are:

Harmony Biosciences Holdings (NASDAQ:HRMY) is the most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 55 points higher than the biotech industry average of 16. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has dropped -2.63% in the past year. It has overperformed other stocks in the biotech industry by 29 percentage points.

Incyte (NASDAQ:INCY) is the second most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Incyte has a valuation score of 86, which is 70 points higher than the biotech industry average of 16. It passed 6 out of 7 valuation due diligence checks.

Incyte's stock has gained 45% in the past year. It has overperformed other stocks in the biotech industry by 77 percentage points.

Exelixis (NASDAQ:EXEL) is the third most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Exelixis has a valuation score of 43, which is 27 points higher than the biotech industry average of 16. It passed 3 out of 7 valuation due diligence checks.

Exelixis's stock has gained 25.92% in the past year. It has overperformed other stocks in the biotech industry by 58 percentage points.

62.99% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 66.92% over the next year.

2.34% of biotech stocks have a Zen Rating of A (Strong Buy), 6.58% of biotech stocks are rated B (Buy), 43.95% are rated C (Hold), 36.09% are rated D (Sell), and 11.04% are rated F (Strong Sell).